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Abstract 
Background: Prosthetic joint infection (PJI) is one of the possible complications 
following total hip arthroplasty (THA). Several studies, but not all, have reported smoking as 
a risk factor of PJI in orthopedic surgery. This study summarizes the most recent evidence 
using a systematic review of whether tobacco use (not only tobacco smoking) is a risk factor 
in developing PJI, specifically after THA. 
Methods: Ovid Medline, EMBASE, Scopus, Web of Science and Cochrane databases 
were searched from inception to July 2019 to identify case-control studies that examined PJI 
risk in tobacco users and tobacco non-user undergoing THA. Publication bias was also 
assessed through funnel plots. 
Results: Searches identified 2,689 articles, 10 of these, involving a total of 20,640 
patients, met the inclusion criteria. The overall odds ratio (pooled OR) to develop either a 
superficial infection, a deep infection or an infection requiring revision surgery for tobacco 
users vs. non-users was 1.54 (95% CI 1.25 - 1.91) when a fixed effect model was used and 
1.56 (95% CI 1.10 - 2.21) when a random effect model was employed. No publication bias 
was observed among the identified studies. 
Conclusions: The findings of the study indicated that tobacco use is associated with 
higher risk of PJI in patients undergoing THA. 
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1 Introduction and background 
Prosthetic joint infection (PJI) is recognized as an infection that involves the joint 
prosthesis and adjacent tissue [1]. Despite both surgical and antimicrobial therapies being 
employed for the management and prevention, one to two percent of patients undergoing 
primary total hip arthroplasty (THA) develop a PJI [2]. These infections can occur at any 
point in time following a primary or a revision surgery; even though about a third of PJIs 
occurs in the first days and weeks after arthroplasty [3]. PJIs are of great concern for both 
patients and health providers as they are associated to repeated or longer hospital admission, 
severe pain, functional deficit, and poor health outcomes and result in a significant economic 
burden and deterioration of patients’ quality of life [4]. According to the National Health 
Services (NHS), the cost associated to elective revision surgery due to PJI was £12,214 [5]. 
As PJI management remains challenging and costly, the most commonly employed approach 
is prevention of such infections through minimizing risk factors. Also, identifying potential 
PJI risk factors is of great clinical significance as it could assist orthopedics surgeons in the 
decision-making process and elaborate interventions to optimize the patient's benefits from 
hip replacement surgery as well. Numerous risk factors have been identified for PJI after total 
joint arthroplasty; these include being of male gender [6-8], obesity [7, 9-11], diabetes [7, 9, 
11, 12], rheumatoid arthritis [13, 14], alcohol abuse [7, 11] and long operating time [3, 6, 8]. 
Tobacco use is another modifiable risk factor that has been considered for post operatory 
complications [15] or PJI after either hip or knee joint replacement [16]. Components of 
cigarette smoke such as nicotine, carbon monoxide and hydrogen cyanide have been found to 
negatively impact the wound healing process [17, 18]. The mechanisms of action of these 
chemicals is different, for example nicotine is a recognized vasoconstrictor thus it reduces the 
blood flow to the skin reducing the mass transport of nutrients with the possibility of tissue 
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ischemia hindering the healing process of injured tissues [18]; carbon monoxide decreases 
the transport of oxygen while hydrogen cyanide inhibits the activity of the enzymes involved 
in the oxidative metabolism and oxygen transport at cellular level [18]. Another possible 
contribution of tobacco usage to the risk of PJI is the reduction in blood flow and 
oxygenation in tissues resulting in low levels of glycose and acidosis [19-21]. Recently, 
smoking has also been proven to be related to impairment of the immune system [22]. 
Hip and knee represent different anatomical locations of the body but, despite the relative 
similar incidence of joint replacement surgery, the risk of PJI is greater after knee 
arthroplasty than hip [10, 23, 24]. Because of these differences, our study considers 
exclusively hip arthroplasty instead of aggregating both joints [16] or even THA, total knee 
arthroplasty, total shoulder arthroplasty, total elbow arthroplasty and total ankle arthroplasty 
[10]. This aggregation results in a weighted risk of PJI based on the relative abundance of 
each joint in the study cohort. Information specifically describing hip replacement were not 
reported; therefore our objective was to address this clear evidence gap. A recent study, very 
comprehensively eliciting risk factors associated to PJI specifically after hip arthroplasty, did 
not consider the smoking/tobacco use status of the patients undergoing arthroplasty [25]; 
moreover, a previous attempt to synthesize the available knowledge through meta-analysis 
could only include studies published before 2015 [26] and thus the reported conclusions may 
not be fully up-to-date. Our purpose was to address this clear knowledge gap assessing the 
role of tobacco use on the risk of developing PJI following hip replacement through a 
systematic literature review and meta-analysis to provide a contemporary synthesis of the 
available evidence to educate clinical advice. 
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2 Material and methods 
2.1 Systematic literature review 
2.1.1 Data source and search strategy 
This review was conducted in line with the Preferred Reporting Items for Systematic 
reviews and Meta-analyses (PRISMA) guidelines [27]. A systematic search through Ovid 
Medline, EMBASE, Scopus, Web of Science and Cochrane databases was carried in July 
2019. A multi-string search strategy was conducted by combining keywords related to the 
intervention, outcomes and type of arthroplasty. The searches were restricted to studies 
published in the English language. The full research strategy and the number of hits for each 
of the databases searched is presented in appendix.  
Bibliographies of eligible articles and clinical guidelines [28, 29] were also searched to 
identify additional studies of interest to the review. 
2.1.2 Eligibility Criteria 
Two authors independently first evaluated the titles and abstracts to identify possibly 
relevant studies, after that, full-text of chosen studies was obtained and inclusion criteria 
applied; reason for exclusion were also recorded. Table 1 shows the eligibility criteria of the 
included studies in this research. In case of disagreement between the reviewers, final 
determination was obtained through consensus.  
Studies addressing total joint arthroplasty in general, without specifying the joint 
replacement site, were included if data reported total hip arthroplasty separately. Similarly, 
studies that explored various risk factor for PJI were included only if presented sufficient data 
for calculating the OR with 95% confidence interval for tobacco users vs. non-users.  
2.1.3 Data extraction 
   
 
5 
 
The following data were extracted from each study that were included: Fist author, 
publication year, country of origin, study design, minimum duration of follow up, sample 
size, number of cases and control, case definitions, confounders controlled. Outcomes of 
interest were the number of observed superficial infections (defined as an infections 
involving “only skin or subcutaneous tissue of the incision), deep infections (defined as 
infections involving the “deep soft tissues” (e.g., fascial and muscle layers)) or revision 
surgeries (regardless of the number of stages) resulting from PJI observed in the cohort over a 
follow-up period of at least 30 days; shorter follow-up were not considered because of the 
possibility of missing infections developing at later stages. Revision surgeries not resulting 
from infections (i.e. aseptic loosening) were not included; similarly reports of generic 
“surgical intervention” following the initial THA were excluded unless a specification that all 
interventions were revisions due to infections. 
2.1.4 Quality assessment of studies included 
Data quality of the included studies was evaluated according to the Newcastle Ottawa 
Scale (NOS) [30]. In case-control studies, NOS evaluates a series of quality parameters 
(selection, confounder, and exposure) in each study. Eight questions with multiple answers 
related to the quality parameters are answered with a possible score of one point or zero for 
each. Therefore, the final NOS score ranges from 0 to 8; the final assessment of the studies 
data quality is defined as follows: 7- 8 points indicate very good studies, 5-6 points indicate 
good studies, 4 points define studies as satisfactory, while studies with 0-3 points are 
considered unsatisfactory .  
2.2 Statistical analysis 
Odds ratios (OR) and 95% confidence interval (95% CI) of PJI for tobacco users vs. non-
users in each study were calculated. Meta-analysis of OR to assess the association between 
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tobacco use and risk of PJI was carried out using the Mantel-Haenszel method for fixed and 
random effect models; the DerSimonian-Laird estimator for 2 was employed and a 
statistically significance level p < 0.05 was applied. Potential publication bias was presented 
graphically by the funnel plot and quantitatively assesses through the Egger’s test. 
Sensitivity analysis considering specific subgroups (specific endpoint reported, 
geographical location of the studies, study design, overall number of infections reported, and 
minimum follow-up duration) was also conducted. 
The possible relation between the minimum follow-up duration of the studies and the 
reported OR of risk of an infectious outcome after THA was analyzed through meta-
regression. 
All analyses were performed in R (version 3.6.1) [31] using the “rmeta” [32] and 
“metafor” [33] packages. 
 
3 Results 
3.1 Search results 
The literature search strategies (Table A 1 - Table A 5) identified 3,536 potentially 
relevant articles from Ovid Medline, EMBASE, Scopus, Web of Science and Cochrane 
databases; in addition to 13 articles from reference chaining that represented articles with 
titles suggesting possible relevance and not identified in the searches. After removing the 
duplications, 2,689 papers remained, then 61 articles were initially selected based on titles 
and abstracts screening for further evaluation. Following a detailed evaluation, which 
included full-text review, 10 studies met the inclusion criteria and were included in the meta-
analysis [34-43].  
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The most common reasons for exclusion was population (n=12), the remaining studies 
were excluded because of: not suitable outcome (n=8) reported, not meeting the intervention 
(n=5) or study type (n=10) criteria or for other reasons (n=16) such as not been published in 
English or the lack of data for the group of interest. All ten included studies were identified in 
the searches and did not originate from other sources. The PRISMA flow diagram (Figure 1) 
illustrates the literature search and selection strategy with the number of studies considered at 
each stage of the process.  
3.2 Cohort characteristics and quality assessment of included studies 
The characteristics of the ten studies included in this review are summarized in Table 2. 
These cohort studies were conducted in the United States (n=5), Switzerland (n=2), Australia 
(n=2), and the United Kingdom (n=1). Studies were predominantly retrospective (n =6) and 
the remaining studies were prospective (n =4); only one study used propensity score 
adjustment for covariates. The sample size of either tobacco users or control (non-users arm) 
varied from 31 to 7,929; the sample size of the meta-analysis was 20,640 participants that 
involved 5,328 tobacco users and 15,312 non-users. The follow-up period ranged from one 
month to five years. The definition of the end points reported varied among the included 
studies, only deep infections were considered in some studies (n=3), while other considered 
only infections resulting in revision surgery (n=3). The occurrence of both superficial and 
deep infections was reported in 4 studies. Overall, the number of observed superficial 
infections was reported in 4 studies, the number of deep infections was reported in 7 studies 
and the number of revision surgeries due to infections was reported in 5 studies.  
Two out of ten studies stated the definition of tobacco non-user (control) cohort while the 
rest did not fully declare the control group inclusion criteria (i.e. never used tobacco or quit 
tobacco at least a certain period of time prior to THA). There was variation in the tobacco 
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users definition among studies and in four studies the clarification criteria were not reported. 
Moreover, the data quality assessment by NOS scale demonstrated that all ten studies had 
reasonable quality for meta-analysis. Five studies scored 7 points, two studies scored 6 
points, and three studies scored 4 points that is interpreted respectively as very good, good, 
and satisfactory quality (Table A 6). 
3.3 Association between tobacco use and PJI 
OR of an infection outcome (superficial infection, deep infection or revision surgery) of 
tobacco users compared tobacco non-users for each of the analyzed studies varied from 0.32 
to 41.28. The overall odds ratio (pooled OR) for the ten studies was 1.54 (95% CI 1.25 - 
1.91) when a fixed effect model was used and 1.56 (95% CI 1.10 - 2.21) when a random 
effect model was employed. The pooled OR was statistically significant for both models (p < 
0.0001 and p = 0.0005 for fixed and random effect model respectively); consequently, using 
tobacco increased the risk of the possible infection endpoints considered in patients 
undergoing THA when compared to the control group (tobacco non-user) (Figure 2). The test 
of heterogeneity of the included studies returned a 2 = 0.010 and I2 = 39%. 
When specific outcomes were considered (Figure 3), the impact of tobacco use was still 
statistically significant when deep infections (7 studies) or revision surgeries (5 studies) were 
individually considered with pooled OR = 1.81 (95% CI 1.39-2.36) and 2.02 (95% CI 1.16-
3.52), respectively. The meta-analysis of the 4 studies reporting the incidence of superficial 
infections after THA revealed that tobacco use was not a statistically significant factor (OR = 
0.89 (95% CI 0.58-1.37)) The heterogeneity of the subgroups reporting superficial or deep 
infections was lower than in the all ten for the studies (2 = 0.10 and I2 = 29% for superficial 
infections and 2 = 0.014 and I2 = 6.4% for deep infections). The heterogeneity of the 
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subgroup reporting revision surgeries after infections was higher than in all the ten studies (2 
= 0.71 and I2 = 56%). 
3.4 Publication bias 
Under visual examination, the funnel plot of the included studies in this meta-analysis of 
infections following THA in tobacco users vs. non-users exhibited symmetry (Figure 4). 
Furthermore, the Egger’s test determined a p value of 0.27 demonstrating that there was no 
potential publication bias among the included studies. 
3.5 Sensitivity analysis 
The risk associated to tobacco use was not different comparing prospective or 
retrospective studies; moreover, studies with minimum follow-up longer than 1 year return 
pooled OR for tobacco use not statistically different from studies with follow-up shorter than 
one year. Similarly, the study size, assessed through the overall number of infections 
reported, did not impact the tobacco use association with infection risk following THA when 
the threshold of 50 total PJI reported in the study was used. Studies conducted in Europe or 
USA did not statistically differ in the risk of reaching the specific end-points of this review; 
the two studies conducted in Australia had much larger confidence intervals and the pool OR 
did not reveal an increased risk of infection for tobacco users (Figure 5). 
3.6 Meta-regression 
The possible impact of the minimum follow-up duration on the pooled OR was assessed 
through meta-regression (Figure 6). The linear regression between individual study reported 
OR and minimum follow-up had an intercept of 1.49 (p < .05) and a slope of 0.0037 (p > 
0.05); therefore the minimum follow-up time was not statistically affecting the pooled ORs.  
 
   
 
10 
 
4 Discussion 
The rationale of this study was to summarize the most recent available results and 
determine the impact of using tobacco (smoking cigarette, cigars or pipes, chewing tobacco) 
on the development of PJI after THA. There has been a contrast in the conclusions of studies 
examining the association between tobacco use and risk of PJI possibly because of small 
sample sizes or unidentified confounders. For instance, the association of smoking with PJI 
was proven in some study [34, 37, 44-46], while other publications did not show such 
relation [39, 42, 47-49]. Previous reviews have partially addressed this question, but this 
systematic review and meta-analysis, endeavored to provide a more contemporary assessment 
of tobacco use on the risk of PJI specifically after THA. As surgical techniques and 
antimicrobial agents/processes evolve while, at the same time, microbial resistance rise, it is 
important to consider the most recent evidence as the situation may have been changed from 
previous studies. The historical timeline of the odds ratio for developing PJI after hip 
replacement did not reach statistical power until around 2013, while the most recent studies 
contributed to the reduction of the level of uncertainty (Figure 7); furthermore the three most 
recent studies were not included in any of the previous systematic reviews. The pooled odds 
ratio of developing PJI for never versus ever tobacco user was previously reported to be 1.67 
(95% CI 1.25 - 2.20) [16][10], thus the impact of using tobacco on the risk of PJI following 
hip replacement observed in this work is in agreement with findings on similar studies. Only 
one systematic review and meta-analysis of studies looked at the relation between smoking 
and deep infection specifically after THA [26]. The overall risk ratio for smoking impact on 
deep infection was 3.71 (95% CI 1.86 - 7.41); these results reveal an increased deep infection 
risk in patients who smoked but are based on only four cohort studies with a limited sample 
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size and do not represent the most recent clinical evidence because of the time elapsed since 
its publication. 
The research findings presented here reflect the recommendation of tobacco use cessation 
before THA; however the present study did not attempt to identify the optimal time of 
abstinence from tobacco use that could improve hip arthroplasty outcome and reduce the rate 
of PJI, moreover the heterogeneous definition of tobacco non-user in the identified study did 
not allow for this type of subgroup analysis. Nevertheless, 6-8 weeks of abstinence from 
smoking before orthopedic surgery have been identified as able to reduce the infection rate 
significantly [50]. 
Our results clearly demonstrate that tobacco use has a detrimental impact on the 
probability of adverse infectious events such as deep infections or revision surgery after hip 
replacement surgery; however the role of tobacco use on the likelihood of superficial is still 
not so clear (Figure 3). These results also suggests that smoking increase the chances of 
developing PJI and that the extent of the infection is influenced by the tobacco use status of 
the patient as tobacco use is a significant factor in developing deep infection but not 
superficial infections. This could be the consequence of tobacco use impacting more the 
organism ability to fight deeper and more extent infections than infections localized on the 
outer skin layers. It is also possible that the number of studies addressing specifically the 
impact of tobacco smoking/use on the surgical superficial infection as outcome have not 
reach a sufficient sample size and further investigation is needed.   
The overall number of patients represented in this review constitute a strength of the study 
along with the geographical spread of the populations considered. Furthermore, despite the 
general negative perception of tobacco as a risk factor, no publication bias has been observed 
among the included studies; this and the general high score in the study quality assessment 
are additional strengths of this work. Nevertheless, some weaknesses are also affecting this 
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review and should be considered when interpreting the results of this investigation. For 
instance, the retrospective design of most of the included studies could lead to lack of 
randomization and to poorly defined confounding factors, and thus it could jeopardize the 
validity of the results [51]. Despite the possible negative impact of a retrospective design, the 
sensitivity analysis did not reveal significant differences between the outcomes of prospective 
and retrospective studies.  
Beside our effort to incorporate all studies reporting infections as primary endpoint or 
infections causing revision to produce more representative data, we found variability in 
infection reporting as well as the duration of follow-up in the included studies that ranged 
between one month and 5 years. It could be hypothesized that short follow-up periods may 
underestimate the risk of PJI occurrence as PJI can develop months and years after the initial 
surgery; however the sensitivity analysis revealed that the pooled OR of studies with follow-
up longer than one year was not different than that of studies with follow-up up to 1 year; 
moreover the results of the meta-regression (Figure 6) revealed that not statistically 
significant role of the study minimum follow-up duration on the pooled OR This demonstrate 
the impact of tobacco on PJI does not varies with the time from surgery; such observation 
was also reported by Kunutsor, Whitehouse [10] that used a similar threshold value. Also, we 
observed heterogeneity between the analyzed studies in terms of tobacco amount consumed 
and definition of non-user as patients who never consumed tobacco or stopped at a certain 
period of time; moreover we were unable to account for the different covariates used in 
individual studies for estimating ORs. Most of the studies controlled for some confounding 
between control and case population; Age, gender, BMI, diabetes, cardiovascular, operating 
time where the most likely factors to be equal, however no single factor was controlled in all 
studies. 
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5 Conclusions 
The findings of this study provide a contemporary synthesis of the available evidence 
related tobacco use as risk factor for PJI in patients undergoing THA. Patients who consume 
tobacco are at a significant greater risk of developing PJI, particularly deep infection or 
infection requiring revision surgery, than patients who do not consume tobacco, thus 
additional preventive measurements are advisable when tobacco users undergo THA in order 
to reduce the likelihood of PJI. 
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Tables 
Table 1. Research eligibility criteria (PICOS format) 
 Inclusion criteria Exclusion criteria 
Population  • Adult patients including both 
males and females who were 
undergoing elective primary 
(unilateral and bilateral or 
simultaneous) and revision total 
hip arthroplasties.  
• Cemented or uncemented. 
• Patients diagnosed with bone 
cancer disorders. 
• Patients-undergoing hemi-
arthroplasty. 
• Non-human population. 
Intervention  Not available  
Comparators tobacco users vs non-user Any other categorization of patient 
population 
Outcomes • Number of patients developing 
peri-prosthetic joint infection 
(deep and/or superficial 
infections).  
• Number of patients developing 
peri-prosthetic joint infection 
requiring revision surgery 
• Minimum follow-up period of 
one month. 
Any other outcome not of interest or 
with follow-up period < 1 month. 
Study type Longitudinal (prospective and 
retrospective) studies. 
• Case reports. 
• Commentary. 
• Letters to editor. 
Language 
restrictions 
Only English language. Any language not English 
 
   
 
   
 
Table 2. Cohort characteristics results included in meta-analysis 
Author 
(publication 
year) 
Country Study design Minimum 
follow up-
period 
(months) 
Confounding 
controlled 
Number of non-
tobacco users 
(infection 
type/end-point) 
Number of 
tobacco users 
(infection 
type/end-point) 
Definition of tobacco 
user 
(case) 
Definition of non-
user 
(control) 
Bedard et al. 
(2018) [34] 
USA Retrospective 30 days Gender, BMI, 
diabetes, dialysis, 
operating time 
7029 (superficial 
63; deep 
1350) 
1208 
(superficial 
7; deep 
39) 
Patients reported 
smoking cigarettes in 
the year before their 
admission for surgery. 
NR 
Choong et al. 
(2004) [35] 
Australia Prospective 16 Age, gender, 
diabetes, 
cardiovascular,  
operating time, 
implant type 
728 (deep 12) 91 (deep 2) NR NR 
Dowsey et al. 
(2008) [36] 
Australia  Retrospective 12 Age, gender, 
diabetes, 
cardiovascular,  
operating time, 
implant type 
1051 (deep 21) 156 (deep 1) NR NR 
Gonzalez et 
al. (2018) 
[38] 
Switzerland Prospective 6 NR 3152 (deep 30) 2046 (deep 38) Definition of smoking 
was not report except 
they include former and 
current smoker under 
the case group. 
NR 
Kapadia et al. 
(2014) [37] 
USA Retrospective 24 Gender, age, BMI 220 (superficial 
0, deep 0,  
revision 0) 
110 (superficial 
3, deep 1,  
revision 5) 
“current” smokers; 
smoked a minimum of 
100 cigarette (or 
nicotine equivalent in 
their lifetime and one 
cigarette within 30 days 
of the operative date.  
NR 
   
 
   
 
NR: not reported; SD: standard deviation; superficial infection: an infection involving “only skin or subcutaneous tissue of the incision”; deep 
infection: an infection involving the “deep soft tissues (e.g. fascial and muscle layers) of the incision” or “any part of the anatomy other than the 
incision”. 
Khan et al. 
(2009) [39] 
UK Prospective 6 ASA score, hip 
Harris score,  
cardiovascular 
diabetes 
917 (superficial 
46, deep 3,  
revision 12) 
268 (superficial 
13, deep 3,  
revision  2) 
Smokers; smoking 
daily in the 30 days 
prior to admission to 
hospital and never 
smoked; patients who 
had never smoked 
regularly at any time in 
their lifetime. 
Never smoked; 
patients who had 
never smoked 
regularly at any 
time in their 
lifetime. 
Lombardi Jr 
et al. (2013) 
[40] 
USA Retrospective 1 Age, BMI, 
diabetes, implant 
type, procedure 
271 (revision 4) 86 (revision  7) Current smokers had an 
average 35, SD 22.8 
pack-years (range 4–
105 pack/years) 
NR 
Lubbeke et 
al. (2014) 
Switzerland Retrospective 21.6 Age, BMI,  1230 (revision 9) 734 (revision 7) NR NR 
Meldrum et 
al. (2005) 
[42] 
USA Retrospective 60 BMI 116 (revision 5) 31 (revision 2) smokers consumed an 
average 1.2 packs of 
cigarettes per day 
(range, 0.25 to two 
packs per day, or 
smoked cigars or pipes, 
and chewed tobacco. 
NR 
Sahota et al. 
(2018) [43] 
USA Retrospective 30 days Age, gender, BMI, 
diabetes, 
cardiovascular,  
operating time 
598 (superficial 
7, deep 1) 
598 (superficial 
5, deep 8) 
Current smokers; 
regularly smoked 
cigarettes in the past 
year before surgery. 
patients who had 
not smoked 
cigarettes in the 
past year before 
surgery 
   
 
   
 
Figures 
 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Flowchart [27]. 
 
   
 
   
 
 
 
Figure 2. Forest plot of risk (reporting odds ratio (OR) and 95% confidence interval (CI) ) of 
cumulative infection outcomes considered (superficial or deep infection and revision surgery) 
after hip replacement between tobacco users and non-users. 
  
   
 
   
 
Figure 3. Forest plot of risk (reporting odds ratio (OR) and 95% confidence interval (CI)) of 
   
 
   
 
superficial infection (a), deep infection (b) and revision surgery as consequence of infection 
(c) after hip replacement between tobacco users and non-users. 
  
   
 
   
 
 
 
Figure 4. Funnel plot of included studies in the meta-analysis. Light gray area represent 90% 
confidence interval and dark gray area represent the 95% confidence area. (S.E.: standard 
error) 
   
 
   
 
 
 
 
Figure 5. Pooled odds ratios (OR) and 95% confidence interval (CI)  of developing PJI after 
total hip replacement comparing tobacco users to non-users grouped according to several 
study characteristics. 
  
   
 
   
 
 
 
 
Figure 6. Correlation between pooled odds ratios (OR) of developing PJI after total hip 
replacement comparing tobacco users to non-users grouped according to reported outcomes. 
Blue line represent meta-regression. Bubble size represent 1/(95% CI) of the study OR.   
 
   
 
   
 
 
 
Figure 7. Timeline of the progression of pooled odds ratio of PJI following THA in tobacco 
users versus non-users (blue line) and 95% confidence interval (light blue area). Numbers 
represent number of studies included in the meta analysis. 
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Search Strategy 
Search strategy and number of hits for the identification of studies reporting periprosthetic 
joint infection after primary total hip arthroplasty in Ovid MEDLINE database (Table A 1).  
 
Table A 1. Ovid MEDLINE® Search strategy. 
# Searches Results 
1 Exp Arthroplasty, Replacement/ 50,550 
2 Total Joint Replacement.mp. 1,783 
3 Total Joint replacement.mp. 1,783 
4 Exp Arthroplasty, Replacement, Hip/ or exp Hip Prosthesis/ 37,920 
5 hip replacements.mp. 2,309 
6 hip arthroplasty.tw. 19,806 
7 hip arthroplasty.mp.  20,597 
8 hip replacement.tw.  10,324 
9 exp Hip Prosthesis/ 22,199 
10 THA.mp 9,652 
11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 73,816 
12 exp Smoking/ or smok*.mp.  310,072 
13 exp Cigarette Smoking/ or exp Cigar Smoking/ or exp Smoking/ 141,087 
14 exp Tobacco/  29,660 
15 exp Nicotine/ 24,655 
16 #12 or #13 or #14 or #15 342,792 
17 #11 and #16 370 
 
 
Search strategy and number of hits for the identification of studies reporting peri-
prosthetic joint infection after primary total hip arthroplasty in EMBASE database (Table A 
2). 
 
Table A 2. EMBASE Search strategy. 
# Search Results 
1 exp Arthroplasty, Replacement/    16,342 
2 Total Joint Replacement.mp.       2,572 
   
 
   
 
3 Total Joint replacement.mp.      2,572 
4 exp Arthroplasty, Replacement, Hip/ or exp Hip Prosthesis/        46,799 
5 hip replacements.mp.       3,070 
6 hip arthroplasty.tw. 24,733 
7 hip arthroplasty.mp.       36,336 
8 hip replacement.tw.       14,253 
9 exp Hip Prosthesis/      44,641 
10 THA.mp.       13,452 
11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10                      79,495 
12 exp Smoking/ or smok*.mp.                                      507,291 
13 exp Cigarette Smoking/ or exp Cigar Smoking/ or exp Smoking/      376,834 
14 exp Tobacco/         47,576 
15 exp Nicotine/         47,701 
16 #12 or #13 or #14 or #15                             558,084 
17 #11 and #16                                              808 
 
 
Search strategy and number of hits for the identification of studies reporting smoking with 
periprosthetic joint infection after primary total hip arthroplasty in Cochrane library database 
(Table A 3).  
 
Table A 3. Cochrane library Search strategy. 
# Search Results 
1 ("arthroplasty"):ti,ab,kw OR ("replacement arthroplasties"):ti,ab,kw OR 
(Joint Prosthesis Implantation):ti,ab,kw OR (Joint Replacement):ti,ab,kw 
OR (Total Joint Replacement):ti,ab,kw 
11,412 
2 ("hip-joint"):ti,ab,kw OR (hip prosthesis):ti,ab,kw OR ("total hip 
arthroplasties"):ti,ab,kw OR ("hip replacement arthroplasty"):ti,ab,kw 
4,061 
3 #1 and #2 2,306 
4 (SMOK*):ti,ab,kw 33,603 
5 #3 and #4 11 
 
 
Search strategy and number of hits for the identification of studies reporting smoking with 
periprosthetic joint infection after primary total hip arthroplasty in Scopus database (Table A 
4).  
   
 
   
 
 
Table A 4. Scopus Search strategy. 
# Search Results 
1 TITLE-ABS-KEY ( hip  AND replacement* )  43,850 
2 TITLE-ABS-KEY ( hip  AND arthroplasty )  47,505 
3 TITLE-ABS-KEY ( hip  AND prosthesis )  52,635 
4 TITLE-ABS-KEY ( joint  AND replacement* )  25,027 
5 TITLE-ABS-KEY ( joint  AND arthroplasty* )  52,409 
6 ( TITLE-ABS KEY ( hip  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( hip  AND arthroplasty ) )  OR  ( TITLE-ABS-
KEY ( hip  AND prosthesis ) )  OR  ( TITLE-ABS-
KEY ( joint  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( joint  AND arthroplasty* ) )  
117,421 
7 ( TITLE-ABS-KEY ( joint  AND infection* )  OR  TITLE-ABS-
KEY ( periprosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( surgical  AND site  AND infection* )  OR  TITLE-ABS-
KEY ( wound  AND infection* )  OR  TITLE-ABS-
KEY ( deep  AND infection* )  OR  TITLE-ABS-
KEY ( superficial  AND infection )  OR  TITLE-ABS-
KEY ( infection* )  OR  TITLE-ABS-KEY ( peri-
prosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( peri  AND prosthetic  AND joint  AND infection ) )  
2,472,938 
8 ( ( TITLE-ABS-KEY ( hip  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( hip  AND arthroplasty ) )  OR  ( TITLE-ABS-
KEY ( hip  AND prosthesis ) )  OR  ( TITLE-ABS-
KEY ( joint  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( joint  AND arthroplasty* ) ) )  AND  ( ( TITLE-ABS-
KEY ( joint  AND infection* )  OR  TITLE-ABS-
KEY ( periprosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( surgical  AND site  AND infection* )  OR  TITLE-ABS-
KEY ( wound  AND infection* )  OR  TITLE-ABS-
KEY ( deep  AND infection* )  OR  TITLE-ABS-
KEY ( superficial  AND infection )  OR  TITLE-ABS-
KEY ( infection* )  OR  TITLE-ABS-KEY ( peri-
prosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( peri  AND prosthetic  AND joint  AND infection ) ) )  
18,622 
9 ( ( TITLE-ABS-KEY ( hip  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( hip  AND arthroplasty ) )  OR  ( TITLE-ABS-
KEY ( hip  AND prosthesis ) )  OR  ( TITLE-ABS-
KEY ( joint  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( joint  AND arthroplasty* ) ) )  AND  ( ( TITLE-ABS-
KEY ( joint  AND infection* )  OR  TITLE-ABS-
KEY ( periprosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( surgical  AND site  AND infection* )  OR  TITLE-ABS-
KEY ( wound  AND infection* )  OR  TITLE-ABS-
16,195 
   
 
   
 
KEY ( deep  AND infection* )  OR  TITLE-ABS-
KEY ( superficial  AND infection )  OR  TITLE-ABS-
KEY ( infection* )  OR  TITLE-ABS-KEY ( peri-
prosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( peri  AND prosthetic  AND joint  AND infection ) ) )  AND  ( LI
MIT-TO ( LANGUAGE ,  "English" ) )  
10 ( ( TITLE-ABS-KEY ( hip  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( hip  AND arthroplasty ) )  OR  ( TITLE-ABS-
KEY ( hip  AND prosthesis ) )  OR  ( TITLE-ABS-
KEY ( joint  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( joint  AND arthroplasty* ) ) )  AND  ( ( TITLE-ABS-
KEY ( joint  AND infection* )  OR  TITLE-ABS-
KEY ( periprosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( surgical  AND site  AND infection* )  OR  TITLE-ABS-
KEY ( wound  AND infection* )  OR  TITLE-ABS-
KEY ( deep  AND infection* )  OR  TITLE-ABS-
KEY ( superficial  AND infection )  OR  TITLE-ABS-
KEY ( infection* )  OR  TITLE-ABS-KEY ( peri-
prosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( peri  AND prosthetic  AND joint  AND infection ) ) ) )  AND  ( T
ITLE-ABS-KEY ( risk  AND factor* ) )  AND  ( LIMIT-
TO ( LANGUAGE ,  "English" ) )  
 
 
2,746 
11 ( ( ( ( TITLE-ABS-KEY ( hip  AND replacement* ) )  OR  ( TITLE-
ABS-KEY ( hip  AND arthroplasty ) )  OR  ( TITLE-ABS-
KEY ( hip  AND prosthesis ) )  OR  ( TITLE-ABS-
KEY ( joint  AND replacement* ) )  OR  ( TITLE-ABS-
KEY ( joint  AND arthroplasty* ) ) )  AND  ( ( TITLE-ABS-
KEY ( joint  AND infection* )  OR  TITLE-ABS-
KEY ( periprosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( surgical  AND site  AND infection* )  OR  TITLE-ABS-
KEY ( wound  AND infection* )  OR  TITLE-ABS-
KEY ( deep  AND infection* )  OR  TITLE-ABS-
KEY ( superficial  AND infection )  OR  TITLE-ABS-
KEY ( infection* )  OR  TITLE-ABS-KEY ( peri-
prosthetic  AND joint  AND infection )  OR  TITLE-ABS-
KEY ( peri  AND prosthetic  AND joint  AND infection ) ) ) )  AND  ( T
ITLE-ABS-
KEY ( risk  AND factor* ) ) )  AND  ( ALL ( smoking ) )  AND  ( LIMI
T-TO ( LANGUAGE ,  "English" ) )  
238 
 
 
Search strategy and number of hits for the identification of studies reporting periprosthetic 
joint infection after primary total hip arthroplasty in Web of Science database (Table A 5).  
 
   
 
   
 
Table A 5. Web of science Search strategy. 
# Search Results 
1 TOPIC: (hip arthroplasty) OR TOPIC: (hip 
replacement) OR TOPIC: (hip prosthesis) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
58,044 
2 TOPIC: (infect*) OR TOPIC: (periprosthetic joint 
infection) OR TOPIC: (deep infection) OR TOPIC:(superficial 
infection) OR TOPIC: (readmission) OR TOPIC: (revision surgery) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
1,813,702 
3 #2 AND #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
12,242 
4 ALL FIELDS: (risk factor*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
1,092,892 
5 #4 AND #3 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
2,109 
 
 
   
 
   
 
Critical appraisal results 
Table A 6. Quality appraisal (case-control studies) for the seven studies included in the meta-analysis 
 Bedard 
et al. 
(2018) 
[34] 
Choong 
et al. 
(2004) 
[35] 
Dowsey 
et al. 
(2008) 
[36] 
Gonzalez 
et al. 
(2018) 
[38] 
Kapadia 
et al. 
(2014) 
[37] 
Khan et 
al. (2009) 
[39] 
Lombar
di et al. 
(2013) 
[40] 
Lubbeke 
et al. 
(2014) 
[41] 
Meldru
m et al. 
(2005) 
[42] 
Sahota et 
al. (2018) 
[43] 
Selection 
Is the case definition adequate?  
a) yes, with independent 
validation 
b) yes, e.g. record linkage or 
based on self-reports 
c) no description 
a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) b (0) a (+1) 
Representativeness of the cases 
a) consecutive or obviously 
representative series of cases 
b) potential for selection biases 
or not stated 
a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) 
Selection of Controls 
a) community controls 
b) hospital controls 
c) no description  
a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) 
Definition of Controls 
a) no history of disease 
(endpoint) 
b) no description of source  
b (0) b (0) b (0) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) 
Confounder 
   
 
   
 
Comparability of cases and 
controls on the basis of the 
design or analysis 
a) study controls for age and 
education 
b) study controls for any 
additional factor 
b (+1) b (+1) b (+1) b (+1) a (+1) b (+1) b (+1) b (+1) b (+1) a (+1) 
Exposure 
Ascertainment of exposure 
a) secure record (e.g. surgical 
records) 
b) structured interview where 
blind to case/control status 
c) interview not blinded to 
case/control status 
d) written self-report or medical 
record only 
e) no description  
e (0) e (0) e (0) d (0) d (0) e (0) d (0) d (0) d (0) d (0) 
Same method of ascertainment 
for cases and controls 
a) yes 
b) no  
b (0) b (0) b (0) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) a (+1) 
Non-Response rate 
a) same rate for both groups 
b) non respondents described 
c) rate different and no 
designation  
b (0) b (0) b (0) a (+1) a (+1) b (0) a (+1) a (+1) a (+1) a (+1) 
Overall score: 
Very Good Studies: 7 to 8 points 
Good Studies: 5 to 6 points 
Satisfactory: 4 points 
4 
Satisfact
ory 
4 
Satisfact
ory 
4 
Satisfact
ory 
7 
Very 
Good 
7 
Very 
Good 
6 
Good 
7 
Very 
Good 
7 
Very 
Good 
6 
Good 
7 
Very 
Good 
   
 
   
 
 
Unsatisfactory Studies: 0 to 3 
points  
